A recent study indicated that a longer progression-free survival was achieved with nivolumab plus ipilimumab than with sunitinib among advanced RCC patients with ≥ 1% PD-L1 expression but not among those with < 1% PD-L1 expression. This evidence concerns the gene CD274 and renal cell carcinoma.